<DOC>
	<DOCNO>NCT01246037</DOCNO>
	<brief_summary>The main question study : 'Is selective beta-blocker treatment safe effective reduce sympathetic overdrive , thereby improve RV function remodel patient iPAH ? ' . In addition determination RVEF , investigator explore beta-blocker therapy affect sympathetic overdrive , remodel RV , single beat elastance , exercise capacity mechanical efficiency . 30 iPAH patient randomize either Bisoprolol- placebo-treatment double-blinded fashion . A cross-over trial design use increase power study assess long-term effect Bisoprolol-treatment -withdrawal . The medication give escalate dose regimen ( describe 'farmacotherapeutisch kompas ' , www.fk.cvz.nl ) treatment monitor along guideline American Heart Association .</brief_summary>
	<brief_title>Beta-blockers i-PAH</brief_title>
	<detailed_description>This clinical study aim provide proof concept safety efficacy beta-blocker treatment PAH-associated right ventricular failure . The protocol propose double blind cross design . The reason choose initial open phase 1 study , start directly placebo control study : 1 . Although drug consider contraindicate studied patient population , common PAH patient receive beta-blocker therapy uncontrolled way ; without report serious side effect 2 . Dose titration study perform basis side-effects moment investigator predict optimal dose safe efficacious . Therefore , safety assessment perform combination assessment pharmaceutical effectiveness . After obtain informed consent , 30 idiopathic PAH patient ( NYHA II-III ) randomly assign either placebo group beta-blocker therapy . For randomization study blind investigator use VUMC computer base procedure close collaboration VUMC pharmacy . In first 4 month study , dose drug gradually increase ; titration scheme base 'farmacotherapeutisch kompas ' ( describe ) monitor accord ACC/AHA/ESC guideline . Up titration perform responsibility experience heart failure cardiologist pulmonologist . MEASUREMENTS Time point 1 , 3 5 ( 6 month period ) : include complete assessment patient - Clinical assessment : physical examination , NYHA class , ECG , routine lab include NT-proBNP urine test proteinuria . - Imaging right ventricular function : primary measure study right ventricular ejection fraction measure mean MRI . Additional MRI echocardiographic measurement perform . ( complete study protocol add supplement ) . - Right Heart Catheterization ( perform local anesthesia ) : Measurements pressure pulmonary artery , right ventricle right atrium , patient breathe room air end-expiration . - Exercise capacity mean maximal incremental cycle test ( CardioPulmonary Exercise Test ) measure maximal work load , VO2 max , anaerobic threshold , heart rate response , oxygen pulse ventilatory efficiency . And mean 6 minute walk distance . - Heart Rate Variability ( HRV ) - Nuclear scanning : comprise PET protocol perform measure 11C-acetaat , oxygen-15-labeled water ( H215O ) ¹¹C-HED uptake right ventricle . A summary protocol add supplement . UP-TITRATION PHASE ( first 4 month ; either placebo Bisoprolol ) : patient monitor every second week supervision experience pulmonologist , specialized PAH , cardiologist , specialize chronic heart failure visit outpatient clinic . If contra-indications find dose increase next step . The investigator start dosage 1,25 mg Bisoprolol daily . Every two week dosage increase 1,25 mg , maximum dosage 10 mg day reach , high tolerate patient . Increasing dosage stop , need dosage reduce , case : - systolic systemic pressure &lt; 90 mmHg - clinical progression heart failure - clinically relevant bradycardia &lt; 60b/min - progression complaint - drop 6 minute walk distance &gt; 15 % The titration procedure placebo titration Bisoprolol . The dosage medication alter maximal four month patient use stable dose rest six month period . Every clinical visit least contain clinical assessment , assessment NYHA class , 6 minute walk distance , ECG Minnesota quality life questionnaire . Every fourth week NT-proBNP , kidney- liver function assess . In addition , patient instruct use diary record his/her symptom body weight . STABLE PHASE : It expect 4 month require reach acceptable dose Bisoprolol . After up-titration phase , patient follow closely remain part six month period , use stable medication dose . The monitoring include continuation diary , monthly visit outpatient clinic include measurement describe up-titration phase telephone call every 4 week office visit . CROSS OVER After six month new measurement do . Thereafter medication taper two week period finally stop . This do prevent patient possible side effect ( rebound tachycardia ) stop medication . The tapering procedure perform third set measurement .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Idiopathic PAH patient Stable PAH specific treatment define No change PAH specific treatment past 6 month No change functional class past 6 month &lt; 10 % change 6 minute walk distance past 6 month Functional class 2 3 In sinus rhythm History systemic hypertension , ischaemic heart disease , valvular disease cardiomyopathy . Asthma Use concomitant medication diuretic , Acenocoumarol PAH target therapy History cardiac arrhythmia use antiarrhythmic drug Sick sinus syndrome systolic hypotension &lt; 90 mmHg AVblock Clinically relevant sinusbradycardia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Beta-blocker</keyword>
	<keyword>Adrenergic Receptor Antagonist</keyword>
</DOC>